The University of Southampton
University of Southampton Institutional Repository

A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia

A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia
Primary resistance to tyrosine kinase inhibitors (TKIs) is a significant barrier to optimal outcomes in chronic myeloid leukemia (CML), but factors contributing to response heterogeneity remain unclear. Using single-cell RNA (scRNA) sequencing, we identified 8 statistically significant features in pretreatment bone marrow, which correlated with either sensitivity (major molecular response or MMR) or extreme resistance to imatinib (eventual blast crisis [BC] transformation). Employing machine-learning, we identified leukemic stem cell (LSC) and natural killer (NK) cell gene expression profiles predicting imatinib response with >80% accuracy, including no false positives for predicting BC. A canonical erythroid-specifying (TAL1/KLF1/GATA1) regulon was a hallmark of LSCs from patients with MMR and was associated with erythroid progenitor [ERP] expansion in vivo (P < .05), and a 2- to 10-fold (6.3-fold in group A vs 1.09-fold in group C) erythroid over myeloid bias in vitro. Notably, ERPs demonstrated exquisite TKI sensitivity compared with myeloid progenitors (P < .001). These LSC features were lost with progressive resistance, and MYC- and IRF1-driven inflammatory regulons were evident in patients who progressed to transformation. Patients with MMR also exhibited a 56-fold expansion (P < .01) of a normally rare subset of hyperfunctional adaptive-like NK cells, which diminished with progressive resistance, whereas patients destined for BC accumulated inhibitory NKG2A+ NK cells favoring NK cell tolerance. Finally, we developed antibody panels to validate our scRNA-seq findings. These panels may be useful for prospective studies of primary resistance, and in assessing the contribution of predetermined vs acquired factors in TKI response heterogeneity.
0006-4971
2738-2755
Krishnan, Vaidehi
86c97b31-bfd8-4f08-96b8-435c5d64d1a8
Schmidt, Florian
edeb7a62-4e98-4399-80a5-3d7a96fe61ed
Nawaz, Zahid
9bd0ad1a-4958-4ef3-b8c4-6436f0a0699d
Rackham, Owen
8122eb1f-6e9f-4da5-90e1-ce108ccbbcbf
et al.
Krishnan, Vaidehi
86c97b31-bfd8-4f08-96b8-435c5d64d1a8
Schmidt, Florian
edeb7a62-4e98-4399-80a5-3d7a96fe61ed
Nawaz, Zahid
9bd0ad1a-4958-4ef3-b8c4-6436f0a0699d
Rackham, Owen
8122eb1f-6e9f-4da5-90e1-ce108ccbbcbf

Krishnan, Vaidehi, Schmidt, Florian and Nawaz, Zahid , et al. (2023) A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood, 141 (22), 2738-2755. (doi:10.1182/blood.2022017295).

Record type: Article

Abstract

Primary resistance to tyrosine kinase inhibitors (TKIs) is a significant barrier to optimal outcomes in chronic myeloid leukemia (CML), but factors contributing to response heterogeneity remain unclear. Using single-cell RNA (scRNA) sequencing, we identified 8 statistically significant features in pretreatment bone marrow, which correlated with either sensitivity (major molecular response or MMR) or extreme resistance to imatinib (eventual blast crisis [BC] transformation). Employing machine-learning, we identified leukemic stem cell (LSC) and natural killer (NK) cell gene expression profiles predicting imatinib response with >80% accuracy, including no false positives for predicting BC. A canonical erythroid-specifying (TAL1/KLF1/GATA1) regulon was a hallmark of LSCs from patients with MMR and was associated with erythroid progenitor [ERP] expansion in vivo (P < .05), and a 2- to 10-fold (6.3-fold in group A vs 1.09-fold in group C) erythroid over myeloid bias in vitro. Notably, ERPs demonstrated exquisite TKI sensitivity compared with myeloid progenitors (P < .001). These LSC features were lost with progressive resistance, and MYC- and IRF1-driven inflammatory regulons were evident in patients who progressed to transformation. Patients with MMR also exhibited a 56-fold expansion (P < .01) of a normally rare subset of hyperfunctional adaptive-like NK cells, which diminished with progressive resistance, whereas patients destined for BC accumulated inhibitory NKG2A+ NK cells favoring NK cell tolerance. Finally, we developed antibody panels to validate our scRNA-seq findings. These panels may be useful for prospective studies of primary resistance, and in assessing the contribution of predetermined vs acquired factors in TKI response heterogeneity.

This record has no associated files available for download.

More information

Accepted/In Press date: 15 February 2023
Published date: 1 June 2023

Identifiers

Local EPrints ID: 501098
URI: http://eprints.soton.ac.uk/id/eprint/501098
ISSN: 0006-4971
PURE UUID: 156f0688-814a-430a-b434-3a6e62b8704a
ORCID for Owen Rackham: ORCID iD orcid.org/0000-0002-4390-0872

Catalogue record

Date deposited: 23 May 2025 16:48
Last modified: 25 May 2025 05:14

Export record

Altmetrics

Contributors

Author: Vaidehi Krishnan
Author: Florian Schmidt
Author: Zahid Nawaz
Author: Owen Rackham ORCID iD
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×